Clinical effect of docetaxel combined with lobaplatin in the treatment of metastatic breast cancer / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
;
(12): 878-880, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-701844
ABSTRACT
Objective To analyze the efficacy and safety of combination of docetaxel and lobaplatin in the treatment of metastatic breast cancer (MBC).Methods The clinical data of 46 patients with MBC who had been administered docetaxel and lobaplatin were retrospectively reviewed.Results All 46 patients were treated for 4 cycles,4 cases achieved complete remission (CR),25 cases achieved partial remission (PR),the effective rate was 63.0% (29/46).The patients were followed up for 12 monthpatients,the progression-free survival time was (8.1 ±0.6) months,2 patients died due to tumor progression.The adverse reactions were mainly granulocyte,thrombocytopenia,anemic,gastrointestinal reaction,articular muscle soreness,mucosa,diarrhea and peripheral edema,mainly Ⅰ ~ Ⅱ degree.Conclusion Docetaxel combined with lobaplatin is well-tolerated and safe for MBC patients,and has less adverse reactions.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS